Intelligence · Patents
Patents expiring in 2036
Annual patent cliff calendar for 2036 — US pharmaceutical patents by expiration date.
- Patents
- 1,428
Quick answer
1,428 indexed pharmaceutical patents have expiration dates in 2036. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9326946
Laminated tablet and manufacturing method therefor
granted -
US 9327023
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
granted -
US 9326975
Substituted pyrazolone compounds and methods of use
granted -
US 9328391
Cloning and expression of HIV-1 DNA
granted -
US 9328387
Antipsychotic treatment based on SNP genotype
granted -
US 9328339
Modified factor IX polypeptides and uses thereof
granted -
US 9328324
System, method and devices for tissue-based diagnosis
granted -
US 9328200
Branched polymeric quaternary ammonium compounds and their uses
granted -
US 9328142
Lipopeptide inhibitors of RAS oncoproteins
granted -
US 9327036
DNA-cell conjugates
granted -
US 9328148
Campylobacter immunogenic compositions and uses thereof
granted -
US 9328077
Bicyclic PKM2 activators
granted -
US 9327258
Porous silica-based particles having smooth surface, method for production thereof and cosmetic comprising such particles
granted -
US 9326978
A3 adenosine receptor allosteric modulators
granted -
US 9327016
Enzymes and methods for cleaving N-glycans from glycoproteins
granted -
US 9326995
Oxides for wound healing and body repair
granted -
US 9327028
Acetylcysteine compositions and methods of use thereof
granted -
US 9326992
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
granted -
US 9326950
Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs
granted -
US 9326991
Nucleotide prodrug compounds and use
granted -
EP 3013366
KOMBINATIONSTHERAPIE MIT EINEM FAKTOR XII-HEMMER UND EINEM C1-HEMMER
granted -
US 9333245
Methods and compositions for treating wounds and reducing the risk of incisional hernias
granted -
US 9333171
Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
granted -
US 9333258
Fine spatiotemporal control of fat removal using NIR light
granted -
US 9334246
Substituted triazines for malaria treatment and chemoprophylaxis
granted -
US 9333248
Methods and composition related to Th-1 dendritic cells
granted -
US 9334250
Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
granted -
US 9334495
Minor groove binder (MGB)-oligonucleotide miRNA antagonists
granted -
US 9334245
Neprilysin inhibitors
granted -
US 9334364
Methods for preparing polymeric reagents and compositions of polymeric reagents
granted -
US 9334306
Leukemia stem cell targeting ligands and methods of use
granted -
US 9334244
Compounds useful as inhibitors of ATR kinase
granted -
US 9333267
Thiol-selective water-soluble polymer derivatives
granted -
US 9334235
Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
granted -
US 9333264
Biocompatible polymeric nanoparticles degrade and release cargo in response to biologically relevant levels of hydrogen peroxide
granted -
US 9333259
Selective fat removal using NIR light and nanoparticles
granted -
US 9333251
Vaccine for protection against Shigella sonnei disease
granted -
US 9333244
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
granted -
US 9333195
Quinuclidine derivatives and medicinal compositions containing the same
granted -
US 9333237
Bone morphogenic protein binding peptide
granted -
US 9333200
Multi-arm polymer prodrugs
granted -
US 9333148
Polymerizable composition and dental material
granted -
US 9334522
Agents and methods to elicit anti-tumor immune response
granted -
WO 2016071511
TRAITEMENT DU SYNDROME D'ACTIVATION MASTOCYTAIRE (SAMA) AVEC LE MASINITIB
granted -
US 2016128999
MASITINIB FOR TREATING HEPATIC CANCER
granted -
US 9340606
Immunization with amyloid-beta oligomers
granted -
US 9340789
UNA oligomer structures for therapeutic agents
granted -
US 9340547
Pyrrolotriazinone derivatives as inhibitors P13K
granted
Frequently asked questions
How many pharma patents expire in 2036?
1,428 published patents in our USPTO index have expiration dates falling in calendar year 2036.